dactolisib and Communicable-Diseases

dactolisib has been researched along with Communicable-Diseases* in 1 studies

Trials

1 trial(s) available for dactolisib and Communicable-Diseases

Article	Year
TORC1 inhibition enhances immune function and reduces infections in the elderly. Science translational medicine, 2018, 07-11, Volume: 10, Issue:449 Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune function in model organisms. The objective of this phase 2a randomized, placebo-controlled clinical trial was to determine whether low-dose mTOR inhibitor therapy enhanced immune function and decreased infection rates in 264 elderly subjects given the study drugs for 6 weeks. A low-dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor that selectively inhibits target of rapamycin complex 1 (TORC1) downstream of mTOR was safe and was associated with a significant ( Topics: Aged; Antibodies, Viral; Communicable Diseases; Dose-Response Relationship, Drug; Everolimus; Humans; Imidazoles; Immunity; Influenza, Human; Mechanistic Target of Rapamycin Complex 1; Quinolines; Up-Regulation; Vaccination	2018

Article

Year

TORC1 inhibition enhances immune function and reduces infections in the elderly.

Science translational medicine, 2018, 07-11, Volume: 10, Issue:449

Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune function in model organisms. The objective of this phase 2a randomized, placebo-controlled clinical trial was to determine whether low-dose mTOR inhibitor therapy enhanced immune function and decreased infection rates in 264 elderly subjects given the study drugs for 6 weeks. A low-dose combination of a catalytic (BEZ235) plus an allosteric (RAD001) mTOR inhibitor that selectively inhibits target of rapamycin complex 1 (TORC1) downstream of mTOR was safe and was associated with a significant (

Topics: Aged; Antibodies, Viral; Communicable Diseases; Dose-Response Relationship, Drug; Everolimus; Humans; Imidazoles; Immunity; Influenza, Human; Mechanistic Target of Rapamycin Complex 1; Quinolines; Up-Regulation; Vaccination

2018